查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球癌症诊断市场-2023年至2028年预测
市场调查报告书
商品编码
1295345

全球癌症诊断市场-2023年至2028年预测

Global Cancer Diagnostics Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 130 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

2021 年癌症诊断市场价值为 124.1 亿美元，预计将以 18.40% 的复合年增长率增长，到 2028 年将达到 404.69 亿美元。

癌症诊断市场是指涉及用于诊断癌症的测试和技术的开发、生产和商业化的医疗行业领域。 这包括广泛的诊断工具，例如成像测试（例如 X 射线、CT 扫描、MRI 扫描）、血液测试、活组织检查和分子诊断测试（例如基因测试和肿瘤标誌物测试）。 癌症诊断市场是医疗保健行业的一个重要领域，因为早期准确的癌症诊断对于有效治疗和改善患者预后至关重要。 癌症诊断市场的主要参与者包括 BioMerieux SA、F. Hoffmann-La Roche Ltd、Sienna Cancer Diagnostics、Insight Medical Genetics 等。 这些公司大力投资研发，开发新技术和解决方案，以满足不断增长的需求。

癌症发病率的上升是推动癌症诊断需求的重要因素。

癌症是全世界死亡的主要原因，其发病率正在以惊人的速度增长。 据世界卫生组织(WHO)称，2020年，将有约1930万新发癌症病例和1000万癌症相关死亡病例。 此外，预计未来20年新发癌症病例数将增加47%，到2040年新发病例数将超过2800万。 随着癌症患者数量的不断增加，人们越来越需要更有效和高效的诊断工具来早期检测和诊断癌症。 癌症的早期发现对于改善患者的预后至关重要，因为它可以进行早期干预和早期治疗，并且可以增加获得良好结果的可能性。

世界各国政府越来越认识到癌症诊断技术的潜力。

例如，2021 年，美国 FDA 授予 Grail Inc. 用于早期癌症检测的液体活检测试突破性器械称号。 这一称号旨在促进新技术的开发和审查，这些新技术显示出为危及生命和不可逆转的衰弱疾病提供更有效的诊断、治疗和预防的潜力。

市场趋势：

  • 2021 年，bioMerieux SA 宣布收购 Canadian Bioinformatics Solutions (BSI)，这是一家蛋白质组学和基因组学分析软件解决方案专家。 通过此次收购，生物梅里埃增强了其在下一代基于测序的癌症诊断方面的能力。
  • 2021 年 6 月，Grail 推出了 Galleri，这是一种血液测试，利用血液中的肿瘤 DNA 片段来识别约 50 种癌症。 该检测在美国可凭处方获得，旨在筛查 50 岁以上癌症风险较高的个人。 Grail 的推出使 Grail 成为针对多种癌症开发基于血液的筛查测试的领导者之一，与 Guardant Health、FreeNorm 和 Thrive Early Inspection 竞争。
  • 2021 年，领先的诊断解决方案提供商 Thermo Fisher Scientific 宣布推出新的 Oncomine Dx Target Test。 使用这种下一代测序仪进行的癌症诊断测试可以检测各种癌症的基因突变。 该测试非常准确，可以检测多个基因的突变，为医生做出治疗决策提供有价值的信息。

从诊断程序来看，癌症诊断市场主要包括临床测试、影像学测试和活检。 预计临床测试领域将在预测期内占据重要的市场份额。 临床检测部分进一步分为血液检测、尿液检测和基因检测。

乳腺癌领域预计将占据重要份额，因为它是全世界女性最常见的癌症之一。

近年来，乳腺癌诊断工具和技术的开发投入快速增加，乳腺癌诊断药物市场有望进一步增长。 根据国防部乳腺癌研究计划报告（2021 年 10 月），截至 2020 年，女性乳腺癌是全球最常诊断的癌症，估计有 230 万新发病例。我在这里。 到 2021 年，仅在美国就有大约 281,550 名女性和 2,650 名男性被诊断出患有浸润性乳腺癌。 随着乳腺癌患者数量的增加，对能够早期发现和及时治疗的癌症诊断技术和产品的需求不断增长。

根据全球癌症观测站（GCO）的数据，人口最多的大陆亚洲将在2020年新增癌症病例数最高，约为950万例。 与此同时，在北美和欧洲，同年新增癌症患者人数超过650万。 烟酒消费量增加、久坐的生活方式、不健康的饮食习惯以及遗传因素导緻美国癌症患者数量大幅增加。 例如，根据美国癌症协会提供的数据，美国新诊断癌症病例为190万例，而2020年报告的新发病例为180万例，相比之下增加了5.6%。 该消息来源还估计，2021 年癌症死亡人数估计为 6,085,570 人，增加了 2,050 人。 癌症诊断病例和死亡率的增加将推动对癌症早期发现的诊断和筛查活动的需求，从而推动美国癌症诊断市场的增长。

内容

第 1 章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场细分
  • 货币
  • 先决条件
  • 基准年和预测年的时间表

第 2 章研究方法

  • 研究设计
  • 调查数据
  • 验证

第 3 章执行摘要

  • 主要发现

第 4 章市场动态

  • 市场促进因素
  • 市场抑制因素
  • 波特五力分析
  • 行业价值链分析

第 5 章全球癌症诊断药物市场：按诊断治疗划分

  • 简介
  • 临床检查
  • 影像检查治疗
  • 活检

第 6 章癌症诊断药物的全球市场：按应用划分

  • 简介
  • 肺癌
  • 乳腺癌
  • 结直肠癌
  • 皮肤癌
  • 胃癌
  • 其他

第 7 章癌症诊断药物的全球市场：按最终用户划分

  • 简介
  • 医院和诊所
  • 诊断中心

第 8 章全球癌症诊断药物市场：按地区划分

  • 简介
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 其他
  • 中东和非洲
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 以色列
    • 其他
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 台湾
    • 印度尼西亚
    • 日本
    • 其他

第 9 章竞争格局与分析

  • 主要公司及战略分析
  • 新兴公司和市场盈利能力
  • 合併、收购、协议和合作
  • 供应商竞争力矩阵

第 10 章公司简介

  • bioMerieux SA
  • F. Hoffmann-La Roche Ltd
  • Sienna Cancer Diagnostics
  • Insight Medical Genetics
  • MetaCell
  • Breath Diagnostics, Inc
  • Arquer Diagnostics Ltd
  • Metabiomics
  • Castle Biosciences, Inc.
  • Exact Sciences Corporation
简介目录
Product Code: KSI061611698

The cancer diagnostics market was valued at US$12.410 billion in 2021 and is expected to grow at a CAGR of 18.40% to be valued at US$40.469 billion by 2028.

The cancer diagnostics market refers to the healthcare industry segment that deals with the development, production, and commercialization of tests and technologies used to diagnose cancer. This includes a wide range of diagnostic tools, including imaging tests (such as X-rays, CT scans, and MRI scans), blood tests, biopsies, and molecular diagnostic tests (such as genetic and tumor marker tests). The cancer diagnostics market is an important segment of the healthcare industry, as early and accurate cancer diagnosis is crucial for effective treatment and improved patient outcomes. Key players in the cancer diagnostics market include bioMerieux SA, F. Hoffmann-La Roche Ltd, Sienna Cancer Diagnostics, and Insight Medical Genetics. These companies are investing heavily in research and development to develop new technologies and solutions to meet the growing demand.

The rising incidences of cancer is a significant factor driving the demand for cancer diagnostics.

Cancer is a leading cause of death worldwide, and the incidence of the disease is increasing alarmingly. According to the World Health Organization (WHO), there were approximately 19.3 million new cancer cases and 10 million cancer-related deaths in 2020. Furthermore, it is estimated that the number of new cancer cases will increase by 47% in the next two decades, with over 28 million new cases expected by 2040. As the number of cancer cases continues to rise, there is a growing need for more effective and efficient diagnostic tools to detect and diagnose the disease at an early stage. Early cancer detection is crucial for improving patient outcomes, as it enables earlier intervention and treatment, which can increase the chances of a positive outcome.

Governments around the world are increasingly recognizing the potential of cancer diagnostics technologies.

For instance, in 2021, the US FDA granted Breakthrough Device designation to Grail Inc.'s liquid biopsy test for early cancer detection. This designation is intended to expedite the development and review of new technologies that demonstrate the potential to provide more effective diagnosis, treatment, or prevention of life-threatening or irreversibly debilitating diseases.

Market Developments:

  • In 2021, bioMerieux SA announced the acquisition of Bioinformatics Solutions Inc. (BSI), a Canadian company specializing in software solutions for proteomics and genomics analysis. This acquisition will enhance bioMerieux's capabilities in next-generation sequencing-based cancer diagnostics.
  • In June 2021, Grail introduced its Galleri blood test, which uses fragments of tumor DNA in the bloodstream to identify almost 50 different cancers. The test is available in the United States with a prescription and is intended for screening individuals over 50 who have an increased risk of cancer. The launch established Grail as one of the leaders in developing blood-based screening tests for various types of cancer, competing with Guardant Health, Freenome, and Thrive Earlier Detection.
  • In 2021, Thermo Fisher Scientific, a leading provider of diagnostic solutions, announced the launch of its new Oncomine Dx Target Test. This next-generation sequencing-based cancer diagnostic test can detect genetic mutations in various types of cancer. The test is highly accurate and can detect mutations in multiple genes, providing physicians with valuable information to guide treatment decisions.

By diagnostic procedures, the global cancer diagnostics market mainly comprises laboratory tests, imaging procedures, and biopsy. During the forecast period, the laboratory test segment is expected to hold a considerable market share. The laboratory test diagnostic procedures segment is further categorized into blood, urine, and genetic tests.

The breast cancer segment is expected to hold a sizeable share as one of the most common types of cancer in women worldwide.

In recent years, there has been a surge in investment in the development of diagnostic tools and technologies for breast cancer, which is expected to fuel further growth in the breast cancer diagnostics market. According to a report by the Department of Defense Breast Cancer Research Program, October 2021, as of 2020, female breast cancer has become the most diagnosed cancer globally, with an estimated 2.3 million new cases. In 2021, about 281,550 women and 2,650 males will be diagnosed with invasive breast cancer in the United States alone. As the number of breast cancer patients grows, there is a heightened demand for cancer diagnostic technologies and products to ensure early detection and prompt treatment.

By geography, the global cancer diagnostics market has been analyzed into North America, South America, Europe, Asia Pacific, and Middle East and Africa.According to data from the Global Cancer Observatory (GCO), Asia, the most populated continent, accounted for the highest number of new cancer cases in 2020, with almost 9.5 million new cases. Meanwhile, North America and Europe combined for more than 6.5 million new cancer cases in the same year. The number of cancer cases has shown significant growth in the US owing to growing alcohol & tobacco consumption, sedentary lifestyle, unhealthy eating habits, and genetic factors. For instance, according to the data provided by the American Cancer of Society, the estimated number of new cancer-diagnosed cases in the US stood at 1.9 million which represented a 5.6% increase in newly diagnosed cases in comparison to 1.8 million new cases reported in 2020. Also, as per the same source, the estimated number of cancer deaths in 2021 stood at 6,08,570, signifying an increase of 2,050 in the number of deaths. Such an increase in cancer-diagnosed cases and the death rate will propel the demand for diagnostics and screening activities for early cancer detection, thereby boosting the market growth of cancer diagnostics in the United States.

Market Segmentation:

BY DIAGNOSTIC PROCEDURES

  • Laboratory Tests
  • Imaging Procedures
  • Biopsy

BY APPLICATION

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Skin Cancer
  • Stomach Cancer
  • Others

BY END-USERS

  • Hospitals and Clinics
  • Diagnostic Centers

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • South Korea
  • Taiwan
  • Indonesia
  • Japan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Data
  • 2.3. Validation

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. GLOBAL CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC PROCEDURES

  • 5.1. Introduction
  • 5.2. Laboratory Tests
  • 5.3. Imaging Procedures
  • 5.4. Biopsy

6. GLOBAL CANCER DIAGNOSTICS MARKET, BY APPLICATION

  • 6.1. Introduction
  • 6.2. Lung Cancer
  • 6.3. Breast Cancer
  • 6.4. Colorectal Cancer
  • 6.5. Skin Cancer
  • 6.6. Stomach Cancer
  • 6.7. Others

7. GLOBAL CANCER DIAGNOSTICS MARKET, BY END-USERS

  • 7.1. Introduction
  • 7.2. Hospitals and Clinics
  • 7.3. Diagnostic Centers

8. GLOBAL CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. South Korea
    • 8.6.4. Taiwan
    • 8.6.5. Indonesia
    • 8.6.6. Japan
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Emerging Players and Market Lucrativeness
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

  • 10.1. bioMerieux SA
  • 10.2. F. Hoffmann-La Roche Ltd
  • 10.3. Sienna Cancer Diagnostics
  • 10.4. Insight Medical Genetics
  • 10.5. MetaCell
  • 10.6. Breath Diagnostics, Inc
  • 10.7. Arquer Diagnostics Ltd
  • 10.8. Metabiomics
  • 10.9. Castle Biosciences, Inc.
  • 10.10. Exact Sciences Corporation